The reading room
Evidence notes and provider dossiers
Read the denominator, the study design and the limits of the claim.
Best GLP-1 providers: what the evidence can tell you
A ten-option starting list, with the boundary between an advertised service and demonstrated outcomes made explicit.
Read the note ↗02Evidence note 01A 20% lower hazard is not a 20-point difference
Reading the SELECT cardiovascular trial without confusing a relative measure, an observed proportion and a personal forecast.
Read the note ↗03Evidence note 02Why a safety-report count is not an event rate
Reports can reveal important signals without providing a denominator, a causal verdict or a fair ranking of medicines.
Read the note ↗04Evidence note 03When a study result becomes a marketing claim
Follow the chain from the original research to the product, population and service being advertised.
Read the note ↗05Evidence methodsA composite endpoint contains more than one outcome
Before repeating a cardiovascular claim, identify what counted as an event and how the result was measured.
Read the note ↗06Research appraisalRead the funding statement, then keep reading the methods
Sponsorship is relevant context. It does not replace examination of the study question, design and reporting.
Read the note ↗07Reading boundariesWhat you can responsibly take from a trial abstract
An abstract can orient a reader while leaving important methods and results outside the available view.
Read the note ↗08Scientific articleESSENCE and MASH: Reading the Biopsy Evidence Before Long-Term Outcomes
The 72-week ESSENCE analysis found meaningful biopsy improvements with weekly injectable semaglutide. Its accelerated MASH approval rests on those findings, while longer follow-up addresses liver complications and survival.
Read the note ↗09Scientific articleOral Orforglipron in ATTAIN-1: Weight Results, Safety, and Formulation
The 72-week trial established a weight-loss benefit over placebo. Interpreting that benefit requires separating study doses from marketed tablets, averages from individual responses, and clinical evidence from care-plan claims.
Read the note ↗